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Abstract
Duchenne Muscular Dystrophy (DMD) is characterised by the absence of dystrophin in muscle
biopsies, although residual dystrophin can be present, either as dystrophin positive (revertant) fibres
or traces. As restoration of dystrophin expression is the end point of clinical trials, such residual
dystrophin is a key factor in recruitment of patients and may also confound the analysis of dystrophin
restoration in treated patients, if, as previously observed in the mdx mouse, revertant fibres increase
with age. In 62% of the diagnostic biopsies reports of 65 DMD patients studied, traces or revertants
were recorded with no correlation between traces or revertants, the patients' performance, or
corticosteroids response. In nine of these patients, there was no increase in traces or revertants in
biopsies taken a mean of 8.23 years (5.8-10.4 years) after the original diagnostic biopsy. This
information should help in the design and execution of clinical trials focused on dystrophin
restoration strategies.
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Introduction
Duchenne muscular dystrophy (DMD) is
caused by mutations in the DMD gene that
prevent the production of functional
dystrophin. These mutations (both large
rearrangements or small mutations) cause a
disruption of the open reading frame (ORF)
impeding the correct protein translation in
DMD patients [1]. In the milder Becker
muscular dystrophy (BMD) intragenic
mutations that maintain the dystrophin mRNA
ORF give rise to internally-deleted but partially
functional dystrophins [1,2].
The diagnosis of DMD is corroborated by the
demonstration of absent dystrophin. In
muscle biopsy sections immunolabelled with
antibodies to dystrophin, this is reflected as a
dystrophin-negative background [3]. However,
very rare, strikingly dystrophin-positive fibres
[4] observed singly or in clusters, have been
described in approximately 50% of DMD cases
[1,4-10]. These “revertant fibres” [11] are also
present in the mdx mouse [4] and the golden
retriever dystrophic dog (GRMD) animal
models [12]. The percentage of revertant
fibres reported in diagnostic biopsies from
DMD patients ranges from 0.01 to 7% [7-
9,11,13-15] while in the mdx mouse they
account for less than 1% of all muscle fibres
[4,16]. A less reported though well known
phenomenon [17] is the presence of traces of
dystrophin, described as patches of below-
normal dystrophin-positive areas visible at the
sarcolemma of muscle fibres, seen in
approximately 20% of DMD patients [6,17].
Traces may be present in up to 25% of the
fibres [17] in DMD patients but do not appear
to occur in the mdx mouse [18]. It is not
known if these traces of dystrophin have a
functional effect. [13] The extent and co-
existence of revertant fibres and dystrophin2
traces have not been well characterized in
DMD boys.
Revertant fibres have internally-deleted
dystrophins, which skip frame-shifting normal
exons inducing favourable skipping events and
restoring the ORF in DMD patients [19]. These
revertant dystrophins often lack the exon
domains flanking deletions [11,13,20] and in
the mdx mouse the mutated exon 23 [19] but
conserve the N and C terminal domains [11]
allowing them to be correctly localized to the
sarcolemma [21]. Studies in both DMD
patients [14,22] and the mdx mouse
[18,19,23] have shown that an individual may
harbor several types of revertant fibres,
consisting of different internally deleted
dystrophins. Proposed mechanisms of their
generation include somatic reversion [24] and
alternative splicing [9,19], the latter described
in the coding region of the DMD gene in both
patients and unaffected individuals [20]. As
an endpoint in several ongoing clinical trials in
DMD is the restoration of dystrophin
expression[25-27], the interpretation of pre-
existing residual dystrophin expression (both
revertant fibres and trace expression) is
important when assessing the efficiency of the
therapeutic intervention. If revertant fibres
increased in number with age, this may
confound the interpretation of the
intervention, especially in studies lasting
several years and in which the increase of
dystrophin is only limited.
Our study provides essential information on
the residual dystrophin expression in a
relatively large population of DMD patients.
We firstly performed a detailed analysis of the
previous diagnostic biopsy reports to assess
the frequency of revertant fibres and
dystrophin traces, and correlated the
dystrophin expression findings to the severity
of the disease progression. Finally, in a subset
of patients we studied the presence of traces
and revertant fibres over time in different
muscles (original diagnostic quadriceps
compared with extensor digitorum brevis,
EDB, or paraspinal muscles).
Materials and Methods
DMD patients
All patients in this study had been diagnosed
and followed up at the Dubowitz
Neuromuscular Centre at Hammersmith
Hospital, London, recently relocated to the
Institute of Child Health & Great Ormond
Street Hospital for Children, London, and at
the Institute of Human Genetics in Newcastle,
both tertiary referral centres for children with
neuromuscular disorders. All patients
presented with a DMD clinical picture,
confirmed by an elevated serum CK, a DMD
gene deletion and absence of dystrophin from
the majority of fibres in a muscle biopsy [28].
Patients had detailed assessments of muscle
strength and functional abilities using the
Hammersmith Motor Ability Score (MAS)
(maximum score 40) [29]. MAS deteriorates
with advancing age and stabilizes or improves
with steroid treatment [29,30]. We collected
data on the MAS at baseline and within the
first 3-6 months, i.e. at the first clinic review
following the initiation of prednisolone
therapy. We correlated the presence of
residual dystrophin expression with the best
MAS and the patient’s age prior to any
intervention including the onset of
prednisolone.
DMD muscle biopsies
Diagnostic biopsies (needle or open) were
obtained from quadriceps muscles. In a subset
of nine wheelchair-dependent patients (mean
age 11.9 years), the extensor digitorum brevis
(EDB) muscles were collected several years
after (mean 8.23 years) their diagnostic
biopsies during surgery for an orthopaedic
procedure (Supplementary table 1).
Muscle biopsy specimens were mounted in
OCT, frozen by immersion in isopentane
cooled in liquid nitrogen and stored at -80°C.
Control sections were taken from a thigh
muscle biopsy of a 41-year old female, with
minimal myopathic changes. All muscle
biopsies were processed by the same
pathology team.34
Patient Mutation Diagnostic biopsy EDB biopsy Time
between
biopsies
(years)
Increase in
revertants?
Age Report Age Report
A Mutation exon 70 3 No revertants 13 Right EDB No
revertants
10.4 No
Ab Mutation exon 70 3 “ 13 Left EDB No
revertants
10.4 No
B Del exons 46-52 5 Revertant
fibres
12 Revertant fibres 7.9 No
C Del exons 3-13 4 Traces 11 Traces 6.9 No
D Del exons 44 3 Revertant
fibres
10 Revertant fibres 6.4 No
E Del exons 50-53 2 No revertants 8 One revertant 6 No*
F Del exons 45-52 4 Faint traces 11 Occasional
traces
7 No
G Del exons 46-51 5.6 Revertant
fibres
12 Revertant fibres 6.7 No
H Del exon 50 8 Traces and
revertants
16 Traces and
revertants
8.8 No
I Del exon 50 7 No revertants,
faint traces
13 Some revertants
and faint traces
5.8 No*
Table 1 Transcript of the reports of the subset of nine patients who were biopsied at two different times: original
(quadriceps) diagnostic biopsy and EDB biopsy. *Patient E’s single revertant fibre in the second biopsy represents
a negligible increase. Patient I showed traces in the original biopsy and revertants and traces in the second one.
Immunohistochemistry
Unfixed frozen sections (6 µm) were
incubated with primary antibodies for 1h at
room temperature, followed by three washes
in PBS, and incubation with biotinylated
secondary anti-mouse or anti-rabbit
antibodies (Amersham UK, 1:200) for 1h at
room temperature. Samples were then
incubated with streptavidin conjugated to
Alexa 594 (Invitrogen UK, 1:1000) for 15 min
at room temperature and washed in PBS
before mounting in Histomount (National
Diagnostics). All samples were examined and
photographed with a Leica epifluorescent
microscope.
The antibodies systematically used were: Dys
3 (exon 13) (1:10), Dys 2 (last 17 amino acids
of C- terminus) (1:20) [31] and Utrophin (DRP2
1:5). In a subset of samples the following
antibodies    were  additionally  used:  β-
Dystroglycan  (BDG),  α-sarcoglycan  (ASG), 
spectrin and dystrophin (Dys1, (rod domain),
P7 (rod domain, exons 56-60) [32] and
Mandys106 (rod domain, exon 43) [33]. All
primary antibodies except P7, a rabbit
polyclonal antibody [32,34] were monoclonal
antibodies from Novocastra Laboratories Ltd
except MANDYS106 (gift from Prof. G. Morris,
Oswestry).
Study of the biopsy reports
The same pathologist, CAS, reported all
muscle biopsies in an 8-year period and
systematically commented on traces and
revertants (Supplementary table 1). To
validate her analysis, the
immunohistochemical analysis in a subset of
10 patients was repeated, analyzed blindly by
two other researchers (LF and VA) and
compared to the original reports
(Supplementary table 2).
When a second biopsy was collected from 9
patients, it was studied and reported by the
same pathologist. When studying the
incidence of residual dystrophin in our
patients, only the original diagnostic reports
were included in the analysis, to avoid
duplication.
Relative intensity measurements
New sections from the sixteen biopsies used
for quantification were stained and analysed
under epifluorescence using a Leica DMR
microscope linked to Metamorph (Universal5
Imaging Inc., Downington, PA) as described
previously[35]. To summarize, each sample
was studied with all eight different antibodies
and four images captured per antibody. In all
experiments, sections from control and
experimental muscles were immunostained
simultaneously and, for each antibody except
utrophin, used to set the capture settings for
the DMD samples. Four images were captured
in each section and captured images were
analyzed by the Metamorph program, to
measure intensities of different areas
(Supplementary figure 1). Ten different
regions of interests (ROIs), each in a different
fibre, were randomly selected per image.
These regions included both the cytoplasm
and the sarcolemma of fibres, so that a
maximum value corresponding to the
sarcolemma and a minimum value
corresponding to the cytoplasm were used in
the analysis. In total, for each experiment, 40
different measurements were taken per
antibody per sample. Measurements of the
intensity of spectrin from serial sections were
used as an internal control to normalise the
measurements and these were expressed as a
percentage of the control for illustration
purposes.
Data analysis
Statistical analysis was performed with the
SPSS package (SPSS Inc, USA). Mann-Whitney
analysis was used to compare the groups.
Results
Revertant fibres are common, but represent
a very low percentage of total muscle fibres
in DMD muscle.
Biopsy reports were examined for references
to residual dystrophin expression. The results
were divided into “no revertant fibres and no
traces present”, “traces of dystrophin only”,
“revertant fibres only” and “revertant fibres
and traces”.
Of 63 DMD biopsy reports examined, 47%
presented revertant fibers, 32 % traces and
36% had neither. 15% showed both revertant
fibres and traces. In the revertant group, 19%
had only one revertant fiber (9% of total
samples), with the rest described as having
“several” as the only reference to the quantity
of revertant fibres. This last group represents
38% of the total.
No correlation between revertant fibres or
traces and Motor Ability Score
Data on the best MAS and the patient’s age
before prednisone treatment was initiated
were available for 35/63 (55%) patients.
Residual dystrophin was mentioned in the
muscle biopsy reports of 18 of these patients,
but not in the remaining 17 patients. Both
patients’ groups demonstrated similar MAS
(Figure 1a).
Figure 1 A) Best Motor Ability Score of DMD
patients whilst steroid naïve versus natural history
data. B) Motor Ability Score of DMD patients with
and without dystrophin residual expression
revertants at baseline and within 3-6 months of
steroid treatment.
Data on the best MAS and the corresponding
patient’s age at the baseline (before starting
steroids) and at the first follow-up (within 3-6
months) of prednisolone treatment were
available for 28/63 (44%) of the patients. Ten
patients had no residual dystrophin and were
started on prednisolone at 5.68±1.68 years
and further 18 had residual dystrophin and
were started on prednisolone at 6.84±1.71
years (age at onset not significantly different).
Prednisolone was given as an intermittent6
Figure 2 Intensity measurements of images captured from sections of 17 biopsies taken from different
patients, after immunostaining with Dys2 were analysed using a semi-quantitative method.
A) The intensity of Dys2 immunostaining is shown as a percentage of the control (2) sample. Arrows
show samples that were referred to as containing traces in the reports. Those samples in which
revertant fibres were reported are highlighted with the # symbol. Error bars +/- 2 s.e.m.
B) Sections immunostained with Dys2 showed significant differences (p<0.001) between those that
were reported to have neither traces or revertant fibres (A) and those that were reported to have
revertant fibres only (B), or traces only (C), or both revertant fibres and traces (D).doi:10.1016/j.nmd.2010.03.007 Author’s copy
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regime using either a regime of 10 days on
and 10 days off (11/13 in the group with no
residual dystrophin and 13/15 in the group
with residual dystrophin) or a regime of 10
days on and 20 days off (2/13 in the residual
dystrophin group and 2/15 in the residual
dystrophin group). The dose was kept at
0.75mg/kg/day regardless of the regime.
There was no difference in the patients’
response to prednisolone at 3-6 months
between those who had residual dystrophin
or not (Figure 1b).
The level of trace dystrophin expression can
be measured semi-quantitatively using the
Metamorph programme
The results of the intensity analysis of the
biopsies were compared with the references
to traces found in their histopathological
reports (n=16). Relative quantitative intensity
measurements were higher in those samples
that had been reported as containing traces
than those which reports did not mention
traces (Figure 2a). When samples were
grouped according to the presence of either
revertant fibres or traces, those that had been
labeled as containing neither revertant fibres
or traces showed significantly less relative
intensity than the other groups (one way
ANOVA, p<0.001) (Figure 2b).
Figure 3 Cryosections from quadriceps muscle biopsies from: muscle from a patient with a deletion in dystrophin
exons 46-51 taken at diagnosis (panels A-F) and six years later (panels G-L) stained with antibodies to dystrophin:
Dys1 (A and G), Dys2 (B and H), Dys3 (C and I) and P7 (D), alpha-sarcoglycan (E and J), beta-dystroglycan (F and K)
and utrophin (L). A cluster of revertant, dystrophin-positive fibres is seen in each series of sections. Revertant
fibres also contain alpha-sarcoglycan (E and J) and beta-dystroglycan (F and K). Utrophin is expressed in the
dystrophin-negative muscle fibres, but is down-regulated in the revertant fibres (L).8
β  -dystroglycan  and  α-sarcoglycan  are  co-
expressed at higher levels in revertant fibers
When analysed by immunohistochemical
techniques, revertant fibres were easily
identifiable from the fibres surrounding them,
with antidystrophin antibodies as they had
strong staining with the Dys1, Dys2 and Dys3
antibodies used in the diagnostic panel. In
addition revertant fibres also had higher levels
of the proteins of the dystrophin associated
complex  β-dystroglycan  and  α-  sarcoglycan. 
The opposite phenomenon was observed in
the case of utrophin, which was present at a
higher level in fibres surrounding revertant
fibres than in the revertant fibres themselves.
This was clearly visible in both diagnostic
quadriceps and EDB biopsies collected years
after diagnosis (Figure 3). Intriguingly, in the
muscle biopsy from a different patient with a
deletion in exons 45-50 (Patient 65,
Supplementary table 1), a cluster of revertant
fibres that was recognised with Dys 2 and
Dys3, but not Dys1 and Mandys106
antibodies, was surrounded by fibres with
traces of dystrophin, recognised by
Mandys106 antibody, which binds to exon 43,
but not the other antibodies (Figure 4). This
clearly illustrates that, in this muscle biopsy,
different epitopes are expressed by the
revertant fibres and the fibres containing
dystrophin traces, indicating that the
mechanisms involved in dystrophin expression
in these two types of fibre can be different.
The number of revertant fibres and amount
of traces do not change with time.
Quadriceps muscle biopsies that had been
collected at the time of diagnosis were
compared with the EDB muscle biopsies
obtained several years later (average 7.3 years
later). It was observed that those patients
whose original biopsy report mentioned
revertant fibres or traces presented the same
features in the report of the more recent EDB
biopsy (Figure 3 and Table 2). In one particular
patient, we cut new sections, stained them
and compared three muscle samples: the
original quadriceps biopsy and both the EDB
and the paraspinal muscle biopsies obtained
6.7 years later at the time of spinal fusion. In
this patient, the dystrophin expression
observed in the quadriceps correlated very
closely with the EDB and paraspinal muscle
(Patient G in tables 1 and supplementary table
1).
Figure 4 Cryosections from biceps muscle from a DMD patient (patient 65, supplementary table 1,del 45-50)
showing a cluster of revertant fibres, clearly visible with anti-dystrophin antibodies Dys2 and Dys3 (A and D) , but
not with Dys1 (B). The same area shows dystrophin traces only stained with Mandys 106 antibody, while
revertant fibres are not visible with this antibody (C).
Discussion
Several studies have previously reported the
pattern of dystrophin expression in DMD
patients; the notion that up to 50% of them
have revertant fibres is fully acknowledged in
the literature [1,5,6,8-10]. Less emphasis has
been placed on the expression of dystrophin
traces in DMD. While from a diagnostic
perspective revertants and traces do not
produce any difficulty, their occurrence could
make the interpretation and quantification of
efficacy of experimental therapies9
complicated. Indeed a number of different
therapeutic strategies aiming to restore
dystrophin expression are currently being
trialed in DMD: these include i) antisense
oligonucleotides which induce exon skipping
in DMD patients with out-of-frame deletions;
ii) PTC124, which is thought to enable the
translation machinery to bypass nonsense
mutations; iii) adeno-associated viruses
coding for mini-dystrophins; iv) plasmid DNA
injection of dystrophin [36]. In these early
studies, restoration of dystrophin expression
following therapy might be relatively limited,
especially in boys receiving low doses of
medicinal product in dose escalation studies.
The possibility that traces of dystrophin or
revertant fibres may be present in different
percentages in different muscles of the body,
or that this expression could increase with age
[19], also needs to be considered. Our study
was therefore aimed to provide more
information on these aspects, by studying the
prevalence of revertant fibres and traces in a
large population of DMD patients. We found
revertant fibres in 47% of the patients, which
corresponds with figures reported in previous
studies. When traces were also considered,
residual dystrophin was found in 64% of the
patients studied. 15% of biopsies studied had
both strongly-staining revertant fibres and
fibres containing unequivocal, but less
intense, dystrophin staining (traces), showing
that both types of fibres may, but not
necessarily, be present in the same muscle.
These dystrophins cannot be distinguished
from each other by immunoblotting; in
addition, western blots may not be sensitive
enough to detect very small amounts of
dystrophin produced in either revertant fibres
or traces, nor quantitative enough at the high
and low end of the signal [38]. Western
blotting requires more muscle than
immunostaining and there was insufficient
muscle from several patients to perform this
analysis. Despite limitations also of this
technique, immunostaining has been used in
many studies in a semi-quantitative manner
[25,26]; in addition the number of dystrophin
positive fibres in a representative section of
muscle has been shown to correlate with the
amount of dystrophin on a western blot [37].
A problem with both western blotting and
immunostaining is sensitivity and specificity of
the antibodies used. Those we have used in
this study are very specific and are widely-
used in routine diagnosis [3,38], but some are
clearly more sensitive than others [25]. The
problem is compounded in studies of
revertant fibres, which express lower than
normal levels of dystrophin [35] and only
express some epitopes of the protein [19].
After consideration of all advantages and
drawbacks of immunostaining and western
blotting, we chose to use immunostaining,
rather than western blotting, for our study.
Studies in the mdx mouse suggest that
revertant fibres could increase in number with
age [19] and anecdotal evidence was found in
some human studies showing a higher
percentage of revertant fibres in older
patients [8,13]. This could be relevant as it
might confuse the analysis of dystrophin
restoration in treated patients. Fanin et al.
(1992)[8] found more than 1% dystrophin-
positive fibres only in DMD patients over 6
years of age and the same group (1995) [13]
reported that older patients had more
revertant fibres per cluster and that there was
a direct correlation between the age of the
patient and prevalence of the percentage of
total fibres that were dystrophin positive.
However a limitation of that study, performed
in 49 individuals, is that the majority of the
biopsies were from patients under 10 years of
age and the lack of longitudinal data on the
same patients. In addition, this study
reported the percentage, not the number, of
dystrophin positive fibres. If the presence of
dystrophin confers a survival advantage to the
fibre, dystrophin negative fibres will be lost,
whereas dystrophin positive fibres will
survive, which may lead to an increase in the
percentage, but not the total number, of
dystrophin positive fibres with time.
In our study, we compared quadriceps
biopsies with EDB biopsies performed in the10
same patients 6-10 years later and find no
obvious increase in numbers of dystrophin
positive fibres, nor did we find larger clusters
of revertant fibres at the later timepoint.
Those patients who had no dystrophin in the
original biopsy did not have any in the second
biopsy and vice versa.
The apparent lack of expansion of revertant
clusters in human DMD muscle may be due to
either lack of functional muscle stem cells, or
to the environment within DMD muscle being
sub-optimal for stem cell function. In mice,
expansion of revertant fibres, which appears
to be a clonal event, is dependent on muscle
regeneration [39] and does not occur under
conditions in which muscle stem cells are
either ablated or not activated [40].
There is ongoing discussion about the
possibility that dystrophin-positive fibres may
offer a biological advantage by lessening the
severity of the disease course in DMD
[13,17,41]. We therefore correlated
dystrophin expression both with the
functional abilities of patients as assessed by
the MAS, whilst steroid naïve, and with
response to corticosteroid treatment.
Although our results should be interpreted
with caution, as only 55% of patients had
detailed assessments at the peak of their
motor ability whilst steroid naïve, our data do
not indicate a difference in function between
patients with or without residual dystrophin
expression. Different explanations could
account for these findings. One possibility is
that the dystrophin produced in these fibres,
although correctly localised, is lacking crucial
binding domains, and is therefore not able to
efficiently protect the fibre from damage.
Indeed, internally deleted dystrophins lacking
an appreciable portion of the rod domain are
ineffective in reducing myofibre necrosis and
restoring muscle function in transgenic mdx
mice [42-45]. Another possibility is that this
phenomenon occurs in so few fibres that it is
not sufficient to be beneficial to properties of
the entire muscle. It is quite likely that the
amount of residual dystrophin had not
reached the threshold level of protein
necessary to effect a functional improvement
in these patients [46].
In previous studies, DMD muscles containing
traces and revertant fibres have been
analysed by western blotting and shown to
contain higher amounts of dystrophin than
muscles without either, but traces or
revertant fibres could not be studied
separately [17]. We have shown that the
presence of traces can be identified not only
by visual inspection of the muscle biopsy
slides but also by a semi-quantitative
capturing method, that reveals dystrophin
protein to be significantly higher in fibres with
dystrophin traces compared to the
neighboring ones [25,26]. The mechanism
responsible for the production of dystrophin
traces may well be different from revertant
fibres, but in both cases, dystrophin is
correctly localized at the sarcolemma. The
molecular basis of trace dystrophin expression
remains to be elucidated, but we show that, in
a biopsy of a patient with a deletion in exons
45-50, a cluster of revertant fibres expresses
different dystrophin epitopes than the
surrounding fibres that contain traces of
dystrophin. This suggests that the dystrophin
proteins produced in this group of fibres may
have been produced by different mechanisms
in this patient.
One limitation of our study is that we have not
been able to study the same muscle analysed
in the original diagnostic biopsy, but
compared dystrophin expression of this
muscle with the EDB muscle. While we cannot
exclude the possibility that a repeated
quadriceps biopsy might have shown a
different percentage of fibres with residual
expression, the very close correlation
between the presence of dystrophin in the
two biopsies (and also a third paraspinal
muscle biopsy in a single patient) is very
encouraging and makes this possibility
unlikely. In addition, the histological analysis
of the EDB muscle showed a clear advanced
dystrophic pathology in all patients,11
suggesting that the degeneration and
regenerative process does occur indeed in this
muscle as well [25].
We conclude that dystrophin expression,
either in revertant fibres, or in fibres
containing trace amounts of dystrophin, is
common phenomenon in DMD patients but,
in contrast to the mdx mouse, we found no
evidence of clonal expansion of revertant
fibres over time, at least when comparing
different muscles. This lack of increase in
number of dystrophin-containing fibres with
age will facilitate the interpretation of
strategies designed to restore dystrophin
expression and facilitates the recruitment of
patients into experimental therapies, provided
the patient had already had a diagnostic
biopsy.
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